$AZTA

Conestoga Capital Advisors’ Q2 2026 investor letter highlighted a shift toward small caps, citing Russell 2000 and Russell 2000 Growth gains, while noting uneven leadership hurt quality-focused strategies. The firm said it sold Azenta, Inc. (NASDAQ:AZTA) after execution issues, weaker life sciences funding, and softer capital equipment demand led management to lower its full-year outlook. Azenta closed Aug. 5 at $31.82.

Starr Ephraim (SVP, Gen Counsel & Secretary) purchased 335 shares of Azenta, Inc. (AZTA) at $24.17 on 2026-07-31.

Azenta (NASDAQ:AZTA) reported Q2 CY2026 results. Revenue rose 12% year on year to $161.2 million, exceeding Wall Street estimates by 8%, and non-GAAP EPS was $0.16, 60% above consensus and down from $0.19 a year earlier. Analysts expect full-year EPS to rise from $0.42 to $0.64 over the next 12 months.

Azenta, Inc. (AZTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 azta-2026q326erxexx991.htm EX-99.1 Document Exhibit 99.1 Azenta Reports Third Quarter Results for Fiscal 2026, Ended June 30, 2026. BURLINGTON, Mass., August 4, 2026 (PR Newswire) – Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the third quarter ended

Azenta (NASDAQ:AZTA) will report Q2 results Tuesday after the bell. The company missed prior-quarter revenue and EPS expectations, with revenue at $144.8 million, flat year on year. For Q2, analysts expect revenue up 3.7% y/y. The stock is up 9.6% over the past month, with an average price target of $27.80 versus $28.13.

Azenta, Inc. (AZTA) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-10.1 3 exhibit101-xexxazentaxthel.htm EX-10.1 Document Execution version Vendor loan agreement between Thelema as Borrower and Azenta Germany GmbH as Lender 1 July 2026 In accordance with Item 601(a)(6) of Regulation S-K, private information has been redacted as indicted in th

The article compares Q1 results across life-sciences tools stocks. West Pharmaceutical Services posted the biggest analyst estimate beat; its shares were up 18% to $323.85. Azenta reported $144.8M revenue (+1% YoY), missing expectations by 2.5%, and shares fell 5.8% to $23.19. Bruker revenue was $823.4M (+2.7%), beating by 3.4%, shares up 56% to $59.30. Illumina revenue was $1.09B (+4.8%), beating by 1.8%, shares up 29.1% to $163.68.

Pomerantz LLP is investigating potential securities fraud claims against Azenta, Inc. (AZTA) on behalf of investors. This comes after Azenta reported lower-than-expected Q2 2026 financial results, including a $149 million goodwill impairment charge and reduced its full-year fiscal 2026 outlook. Following this news, Azenta's stock price dropped by over 25%.

Azenta, Inc. (NASDAQ: AZTA) has granted William E. Martin III, President of Multiomics, 17,790 restricted stock units (RSUs) as compensation under the company's Equity Incentive Plan. These RSUs, valued at $24.24 per share, will vest over three years with installments on April 18, 2027, April 18, 2028, and April 18, 2029. Following this grant, Martin III directly holds 17,790 common shares tied to this award.

Azenta, Inc. (Nasdaq: AZTA) is scheduled to announce its fiscal second quarter 2026 earnings on Wednesday, May 6, 2026, before market open. The company will also host a conference call and live webcast on the same day at 8:30 a.m. Eastern Time to discuss its financial results. Investors and media can access the webcast via Azenta's investor relations website, with a replay available from May 7, 2026.